中藥股拉昇 大理藥業等多股漲停 多地出台中醫藥利好政策
格隆匯6月16日丨大理藥業、盤龍藥業、亞寶藥業漲停,精華製藥、同仁堂、信邦製藥、太安堂、龍津藥業、康惠製藥、西藏藥業等跟漲。近日,上海、天津、安徽等多地相繼出台政策支持中醫藥傳承發展。上海提出鼓勵源於古代經典名方的中藥複方製劑、具有長期臨牀療效驗證的醫療機構製劑申請上市。天津發布《天津市中醫藥強市行動計劃(2022-2025年)》徵求意見稿指出,推進中醫藥事業和產業高質量發展,建設中醫藥強市。安徽出台《安徽省促進中醫藥振興發展行動計劃(2022-2024年)》,力爭3年全省中藥產業和中醫藥健康服務全產業鏈總產值達到4000億元,產業規模和競爭力進入全國第一方陣。業內人士認為,中醫藥高質量發展已成為業界共識,相關部門陸續發佈中醫藥支持政策,中醫藥行業具備長期投資價值。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.